Cancer Family
Secondary Malignant Neoplasm
CI-CAN-00000346SMNExplore in graph →
4,275 active trials56 approved drugs532 evidence items
- NCIt
- C4968
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000346SMNExplore in graph →
Clinical trials
14,674 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,963)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07744698 | Metronomic Oral Paclitaxel Plus PD-1/ PD-L1 Inhibitor Maintenance in Advanced Lung Cancer (PULSE Study)(PULSE) | recruiting | Phase 4 | 107 | Anhui Provincial Cancer HospitalOTHER | 1 | Aug 4, 2026 | clinicaltrials |
| NCT05285358 | Pressurized Intraperitoneal Aerosolized Nab-Paclitaxel in Combination With Gemcitabine and Cisplatin for the Treatment of Biliary Tract Cancer Patients With Peritoneal Metastases | recruiting | Phase 1 | 12 | City of Hope Medical CenterOTHER | 1 |
| Aug 3, 2026 |
| clinicaltrials |
| NCT05433142 | Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma | recruiting | Phase 1 | 307 | Xencor, Inc.INDUSTRY | 5 | Aug 3, 2026 | clinicaltrials |
| NCT05443087 | TARGETed Therapy Drug MONITOring in DIGestive Oncology(TARGETMONITO) | recruiting | N/A | 330 | UNICANCEROTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT06081244 | NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT-TN-III)(ADAPT-TN-III) | recruiting | Phase 3 | 348 | Women's Cancer Study Group GmbHOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT06819228 | Window Trial of Fluorescently Labeled Panitumumab (Panitumumab-IRDye800) in Head and Neck Cancer | recruiting | Phase 1 | 70 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT06877637 | On-treatment Surveillance of Tumor Evolution and Response to Systemic Treatment in Bile Duct and Liver Cancer(BILLIONSTARS) | recruiting | — | 150 | Region SkaneOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT07179900 | Radiotherapy Combined With QL1706 and Bevacizumab for Unresectable Non-metastatic Hepatocellular Carcinoma | recruiting | Phase 2 | 60 | Hebei Medical University Fourth HospitalOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT07227402 | A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)(LITESPARK-033) | recruiting | Phase 3 | 904 | Merck Sharp & Dohme LLCINDUSTRY | 23 | Aug 3, 2026 | clinicaltrials |
| NCT07300241 | Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma | recruiting | Phase 1 | 30 | Neomorph, IncINDUSTRY | 1 | Aug 3, 2026 | clinicaltrials |
| NCT07611825 | Gut Microbiota Modulation for Immunotherapy Resensitization in Advanced Renal Cell Carcinoma(REMEDY-RCC) | recruiting | Phase 2 | 33 | Jinling Hospital, ChinaOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT04521764 | A Vaccine (MV-s-NAP) for the Treatment of Patients With Invasive Metastatic Breast Cancer | recruiting | Phase 1 | 54 | Mayo ClinicOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT04747054 | Study on the Efficacy of Treatment by Radiotherapy and Pembrolizumab in Newly Diagnosed Metastatic Head & Neck Cancers(PembroMetaRT) | recruiting | Phase 3 | 102 | UNICANCEROTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT04912765 | Neoantigen Dendritic Cell Vaccine and Nivolumab in HCC and Liver Metastases From CRC | recruiting | Phase 2 | 60 | National Cancer Centre, SingaporeOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT05759923 | First-in-human Phase I Study to Evaluate Safety, Tolerability and Antineoplastic Activity of OATD-02 in Patients With Selected Advanced and/or Metastatic Solid Tumours | recruiting | Phase 1 | 40 | Molecure S.A.INDUSTRY | 1 | Jul 31, 2026 | clinicaltrials |
| NCT06367257 | App-based Recording and Optimization of the Nutritional Status in Patients With Head and Neck Tumors During and After Radio(Chemo)Therapy | recruiting | N/A | 148 | University of Erlangen-Nürnberg Medical SchoolOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT06866262 | Inulin Gel in Combination With Ipilimumab and Nivolumab for the Treatment of Metastatic or Locally Advanced Kidney Cell Cancer, ICON Trial | recruiting | Phase 1 / Phase 2 | 55 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT06947668 | Immune Biomarker Study for Cisplatin-ineligible Patients Receiving Chemoradiotherapy With Docetaxel(DoIT_Neck) | recruiting | — | 250 | University of Erlangen-Nürnberg Medical SchoolOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT07121595 | Personalized Neck Radiation Therapy Directed by Sentinel Lymph Node Biopsy for the Treatment of Oral Cavity Squamous Cell Carcinoma, PRECEDENT Trial | recruiting | Phase 2 | 50 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT07129252 | A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors(BRAVESST2) | recruiting | Phase 1 / Phase 2 | 150 | Crinetics Pharmaceuticals Inc.INDUSTRY | 2 | Jul 31, 2026 | clinicaltrials |
| NCT07132645 | An Investigational Scan ([68Ga] Ga-FAPI-04 PET/CT) for the Imaging of Patients With High-Grade Neuroendocrine Cancer | recruiting | Early Phase 1 | 30 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT07268131 | TITAN-HCC: Neoadjuvant and Adjuvant QL1706 With TACE in Resectable Hepatocellular Carcinoma Beyond Milan Criteria(TITAN-HCC) | recruiting | N/A | 30 | Fudan UniversityOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT07402343 | Tarlatamab for SCLC Brain Metastases(T-BRAIN) | recruiting | Phase 2 | 35 | Maastricht University Medical CenterOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT07419841 | A Phase 1 Study of the Safety and Tolerability of CTX-10726 | recruiting | Phase 1 | 70 | Compass TherapeuticsINDUSTRY | 1 | Jul 31, 2026 | clinicaltrials |
| NCT07628634 | Feasibility Study on the Effect of a Methionine-Reduced Diet on Serum Levels in Pts w/ Solid Tumors | recruiting | Early Phase 1 | 25 | University of California, IrvineOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT07629817 | Surgery vs. Radical Chemoradiotherapy for Esophageal SCC After Neoadjuvant Immunochemotherapy(HCHTOG2603) | recruiting | Phase 3 | 1,044 | Henan Cancer HospitalOTHER_GOV | 1 | Jul 31, 2026 | clinicaltrials |
| NCT02727803 | Personalized NK Cell Therapy in CBT | recruiting | Phase 2 | 100 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT04657068 | A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 542 | Artios Pharma LtdINDUSTRY | 4 | Jul 30, 2026 | clinicaltrials |
| NCT05663710 | Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCC | recruiting | Phase 1 / Phase 2 | 100 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT05751434 | A Study on the Effects of Exercise Therapy on Signs of Prostate Cancer | recruiting | Phase 2 | 102 | City of Hope Medical CenterOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT06325046 | Adaptive Radiation Therapy (ART) Stereotactic Ablative Body Radiotherapy (SABR) for Primary Localized Prostate Cancer | recruiting | N/A | 164 | Mayo ClinicOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT06486883 | Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype(PONTIAC) | recruiting | Phase 2 | 200 | MedSIROTHER | 10 | Jul 30, 2026 | clinicaltrials |
| NCT07172256 | CUE-101with Pembrolizumab for Locally Advanced HPV+HNSCCs | recruiting | Phase 2 | 30 | Yale UniversityOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT07179770 | Effects of Belzutifan on 89Zr-DFO-girentuximab PET Uptake in Patients With Renal Cell Carcinoma (RCC) | recruiting | Phase 1 | 12 | NYU Langone HealthOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT07634380 | Sitagliptin With Pembro in RCC and Melanoma | recruiting | Phase 1 | 64 | Fernando Maciel BarbosaOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT03526835 | A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 560 | Merus B.V.INDUSTRY | 7 | Jul 29, 2026 | clinicaltrials |
| NCT04113486 | Expression Levels of Nicotinamide Metabolism-related Protein (NMAP) in Newly Diagnosed Renal Cancer and Non-renal Cancer Populations(ENRC) | recruiting | — | 400 | Xinhua Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT04198766 | Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) | recruiting | Phase 1 / Phase 2 | 340 | Inhibrx Biosciences, IncINDUSTRY | 4 | Jul 29, 2026 | clinicaltrials |
| NCT04990609 | EUS-RFA PANCARDINAL-1 Trial | recruiting | Phase 2 | 60 | The University of Texas Health Science Center, HoustonOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT05665361 | Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC) | recruiting | Phase 1 / Phase 2 | 100 | National Cancer Institute (NCI)NIH | 1 | Jul 29, 2026 | clinicaltrials |
| NCT05756569 | Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology | recruiting | Phase 2 | 25 | Emory UniversityOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT06562192 | Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers | recruiting | Phase 1 | 162 | Novartis PharmaceuticalsINDUSTRY | 10 | Jul 29, 2026 | clinicaltrials |
| NCT07229417 | A Trial Evaluating the Efficacy of Ivonescimab in Metastatic Endocrine Refractory HR-positive HER2-negative or Triple Negative Invasive Lobular Carcinoma | recruiting | Phase 2 | 29 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT07564232 | Phase 1 Study Of LNK001 In Advanced Or Metastatic Clear Cell Renal Cell Carcinoma | recruiting | Phase 1 | 40 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT05263050 | Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors | recruiting | Phase 2 | 111 | Fox Chase Cancer CenterOTHER | 1 | Jul 28, 2026 | clinicaltrials |
| NCT06150664 | A Phase 1 of CTX-8371 in Patients With Advanced Malignancies | recruiting | Phase 1 | 85 | Compass TherapeuticsINDUSTRY | 1 | Jul 28, 2026 | clinicaltrials |
| NCT06347068 | Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T Cells | recruiting | Phase 1 | 42 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Jul 28, 2026 | clinicaltrials |
| NCT06835387 | Study of NALIRIFOX in Advanced Unresectable Small Bowel Tumors | recruiting | Phase 2 | 36 | Tiago Biachi de CastriaOTHER | 1 | Jul 28, 2026 | clinicaltrials |
| NCT07059494 | Atezolizumab and Bevacizumab in Combination With Y^90 Radioembolization in HCC for Liver Transplant | recruiting | Phase 4 | 40 | Icahn School of Medicine at Mount SinaiOTHER | 1 | Jul 28, 2026 | clinicaltrials |
Data updated 24 days agoSource updated Aug 4, 2026source: clinicaltrials